February 7, 2024

Consolidated Financial Results
for the Nine Months Ended December 31, 2023
Terumo Corporation〔IFRS〕
Company name: TERUMO CORPORATION
Listing:
Tokyo Stock Exchange
Securities code:
4543
URL:
https://www.terumo.com/
Representative:
Shinjiro Sato, President and CEO
Inquiries:
Kenichi Hata, General Manager, Investor Relations Dept.
Telephone:+81-3-6742-8550
Scheduled date to file quarterly securities report:
February 9, 2024－
Scheduled date to commence dividend payments:
Preparation of supplementary material on quarterly financial results: Yes
Holding of quarterly financial results briefing:
Yes (for Securities analysts, Institutional
investors)(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the nine months ended December 31, 2023 (from April 1, 2023 to
December 31, 2023)(1) Consolidated operating results (cumulative)
Revenue
Nine months
ended
December 31,
2023
December 31,
2022(Percentages indicate year-on-year changes.)

Operating profit

Profit before tax

Profit attributableto owners of theparentProfit for theperiodTotal
comprehensive
incomeMillions ofyen%Millions ofyen%Millions ofyen%Millions ofyen%Millions ofyen%Millions ofyen%

682,951

10.5

105,51912.8

105,743

14.8

79,897

13.8

79,897

13.8

144,6624.0

617,99318.1

93,514(1.0)

92,100(1.0)

70,180(2.1)

70,180(2.1)

139,144

36.4

Basic earnings
per share
Nine months
ended
December 31,
2023
December 31,
2022(Note) Adjusted operating profit

Diluted earnings
per share
Yen

Yen

107.33107.29

93.25

93.21

December 2023:119,733 million yen

December 2022: 109,607 million yen(2) Consolidated financial position
Total assets
As ofTotal equity

Equity attributable toowners of the parent

Ratio of equity
attributable to owners of
the parent to total assets

Millions of yen

Millions of yen

Millions of yen%

December 31, 2023

1,691,667

1,216,011

1,216,011

71.9

March 31, 2023

1,602,225

1,111,063

1,111,063

69.3

2. Cash dividends
Annual dividends per shareFirst quarter-end

Second quarter-end

Third quarter-end

Yen

Yen

Yen

Fiscal year ended
March 31, 2023
Fiscal year ending
March 31, 2024

－

19.00

－

－

22.00

－

Fiscal year-end

Fiscal year ending
March 31, 2024
(Guidance)

Total

Yen

Yen

21.00

40.00

22.00

44.00

(Note) Revision from the dividend guidance, which is published most recently: None
3. Consolidated Financial Guidance for the Fiscal Year Ending March 31, 2024 (From April 1, 2023 toMarch 31, 2024)(Percentages indicate year-on-year changes.)
Adjusted operating
profitRevenue
Fiscal year ending
March, 2024

Profit for the year
attributable to ownersof the parent

Operating profit

Basic Earnings per
share

Millions of yen%

Millions of yen%

Millions of yen%

Millions of yen%

Yen

906,000

10.5

157,500

14.1

140,000

19.3

105,000

17.5

141.18(Note 1) Revision of guidance for the fiscal year ending March 31, 2024, which is published most recently: Yes
Regarding the guidance for the fiscal year, please refer to the February 7, 2024 press release “NoticeConcerning Revision of the Full-Year Financial Guidance for Fiscal Year Ending March 31, 2024
(FY2023)”.
(Note 2) The Company has resolved at the meeting of the Board of Directors held on August 9, 2023 to acquire its
treasury shares. Basic earnings per share is calculated by taking into consideration effects of theacquisition of its treasury shares.
(Note 3) Assumed exchange rate for the fiscal year ending March 31, 2024: USD1=JPY143, EUR1=JPY156

*Notes(1) Changes in significant subsidiaries during the current quarterly consolidated cumulative period (changes in
specified subsidiaries resulting in the change in scope of consolidation): None
New － Company (Company Name) －, Excluded － Company (Company Name) －(2) Changes in accounting policies and changes in accounting estimates(i) Changes in accounting policies required by IFRS: Yes(ii) Changes in accounting policies other than (i): None(iii) Changes in accounting estimates: None
* Please refer to [attached materials], page 11, “2. Condensed Quarterly Consolidated Financial Statements (4)Notes Pertaining to Condensed Quarterly Consolidated Financial Statements (ii) Changes in accounting
policy”.
(3) Number of shares outstanding (common stock)(i) Number of shares outstanding at the end of
the period (including treasury shares)

As of December 31,
2023

747,682,540 shares As of March 31, 2023

747,682,540 shares(ii) Treasury shares at the end of the period

As of December 31,
2023

4,657,129 shares As of March 31, 2023

3,074,907 shares(iii) Average number of shares during theperiod (cumulative quarterly)

Nine months ended
December 31, 2023

Nine months ended
December 31, 2022

752,618,446 shares

744,422,133 shares* Quarterly financial statements are not subject to quarterly reviews by certified public accountants or audit firms.
* Explanation on appropriate use of financial guidance and other special notes
1. Forward-looking statements, including financial guidance, contained in these disclosure materials are based on
currently available information and assumptions believed to be reasonable by management. This is not apromise or guarantee by the Company that it will achieve these goals. In addition, actual results may differ
significantly due to various factors. For the assumptions that are the premise of the financial guidance and theprecautions for using the financial guidance, refer to attached materials, page 5, “1. Overview of Financial
Results for the Nine Months Ended December 31, 2023 (3) Guidance, including the Consolidated Financial
Results for the Fiscal Year Ending March 31, 2024”.
2. Adjusted operating profit factors out amortization expense for intangible assets recognized in acquisitions andnon-recurring profit or loss from operating profit. In addition, adjusted operating profit is consistent withsegment profit. We are disclosing adjusted operating profit as we are using it as a performance indicator.

Terumo Corporation (4543) Consolidated Financial Results for the Nine Months Ended December 31, 2023

 Table of contents of attached materials
1. Overview of Financial Results for the Nine Months Ended December 31, 2023 .................................................. 2(1) Overview of Consolidated Business Results ..................................................................................................... 2(2) Overview of Consolidated Statement of Financial Position .............................................................................. 5(3) Guidance, including the Consolidated Financial Results for the Fiscal Year Ending March 31, 2024 ............. 5
2. Condensed Quarterly Consolidated Financial Statements ..................................................................................... 6(1) Condensed Quarterly Consolidated Statement of Financial Position ................................................................ 6(2) Condensed Quarterly Consolidated Statement of Profit or Loss and Condensed Quarterly Consolidated
Statement of Comprehensive Income ............................................................................................................. 8(3) Condensed Quarterly Consolidated Statement of Changes in Equity ............................................................. 10(4) Notes Pertaining to Condensed Quarterly Consolidated Financial Statements ................................................ 11(i) Going concern assumption ............................................................................................................................. 11(ii) Changes in accounting policy ....................................................................................................................... 11(iii) Segment information ................................................................................................................................... 11(iv) Impairment of non-financial assets ............................................................................................................. 14(v) Material subsequent events .......................................................................................................................... 14－ 1 －Terumo Corporation (4543) Consolidated Financial Results for the Nine Months Ended December 31, 2023

1. Overview of Financial Results for the Nine Months Ended December 31, 2023
(1) Overview of Consolidated Business Results
In the first nine months of the current fiscal year (from April 1 to December 31, 2023), the Group’s sales trended
strongly amid growing demand for products globally and the effects of foreign exchange rates.
Financial results for the first nine months are as follows:(Unit: Millions of yen)
For the ninemonths ended
December 31,
2022

For the ninemonths ended
December 31,
2023

Revenue

617,993682,951

10.5

6.1

Gross profit

318,347

354,840

11.5

7.4

Adjusted operating profit

109,607

119,733

9.2

5.6

Operating profit

93,514

105,519

12.8

9.4

Profit before tax

92,100105,743

14.8－

Profit for the period

70,18079,897

13.8－

Profit for the period
attributable to owners of theparent70,18079,89713.8－

Growthexcluding
FX impact (%)

Growth (%)

Revenue by geographic areas for the first nine months is as follows:(Unit: Millions of yen)
For the ninemonths ended
December 31,
2022

For the ninemonths ended
December 31,
2023

Americas212,363

238,202

12.2

7.0

Europe118,615

139,022

17.2

6.5

China

56,62860,062

6.1

5.5

Asia and others

73,341

86,98018.6

14.0

Overseas total

460,948524,267

13.7

7.8

Japan

157,044

158,684

1.0

1.0

Total

617,993682,951

10.5

6.1

Geographic areas－ 2 －Growth (%)

Growthexcluding
FX impact (%)

Terumo Corporation (4543) Consolidated Financial Results for the Nine Months Ended December 31, 2023

Revenue
Revenue totaled ¥683.0 billion, an increase of 10.5 % versus the same period in the previous fiscal year.
Overseas, revenue increased 13.7 % year on year owing to increased demand in TIS (catheter) division and forblood centers business, along with the effects of foreign exchange rates.
In Japan, revenue increased by 1.0 % year on year, as strong sales of infusion related products and TIS divisionoffset the decline in sales of nutrition products in Hospital Care Solutions division, which was sold in theprevious fiscal year.
ProfitGross profit totaled ¥354.8 billion, an increase of 11.5% versus the same period in the previous fiscal year,
because of the higher revenue.
Adjusted operating profit was ¥119.7 billion, an increase of 9.2% versus the same period in the previous fiscal
year. This was because the increase in gross profit was partially offset by an increase of selling, general andadministrative expenses.
Operating profit, profit for the period and profit for the period attributable to owners of the parent each increased
amid the increase in gross profit.
Adjusted operating profit is a non-IFRS performance indicator that we disclose. Adjusted operating profit factors
out amortization expense for intangible assets recognized in acquisitions and non-recurring profit or loss fromoperating profit. In addition, adjusted operating profit is consistent with segment profit.
Adjusted operating profit is being used as an indicator for corporate management to grasp earnings performancein each business as a part of our goal to achieve sustainable growth in the mid- to long-term. We believe this isalso effective data for individuals using our financial statements to assess the Group’s earnings.

－ 3 －Terumo Corporation (4543) Consolidated Financial Results for the Nine Months Ended December 31, 2023

Revenue results of the reportable segments are as follows:(Unit: Millions of yen)
For the ninemonths ended
December 31,
2022

For the ninemonths ended
December 31,
2023

Growth (%)

Growthexcluding
FX impact (%)

Revenue

358,907407,700

13.6

8.2(Overseas)

320,528

367,542

14.7

8.6(Japan)38,37940,158

4.6

4.6

Revenue

145,511147,279

1.2

(0.4)

(Overseas)

35,361

37,8627.1

0.4(Japan)110,149

109,417

(0.7)

(0.7)

Revenue

113,388

127,799

12.7

7.8(Overseas)

105,058

118,863

13.1

7.9(Japan)

8,329

8,936

7.3

7.3

Segment
Cardiac and
VascularCompany
Medical Care
SolutionsCompany
Blood and Cell
Technologies
Company

Cardiac and Vascular Company
Overseas, revenue increased 14.7% year on year driven by TIS (catheter) division and Neurovascular division. In
Japan, revenue increased 4.6% year on year as there was a recovery in the number of endovascular treatment
procedures. As a result, global revenue increased 13.6% over the same period of the previous fiscal year to¥407.7 billion.
Medical Care Solutions Company
In Japan, revenue declined by 0.7% year on year, as increased sales of infusion related products and sales of
Pharmaceutical Solutions division partially offset the decline in sales of nutrition products in Hospital Care
Solutions division, which was sold in the previous fiscal year. Overseas, revenue increased 7.1% year on year
along with the effects of foreign exchange rates. As a result, global revenue increased 1.2% over the same periodof the previous fiscal year to ¥147.3 billion.
Blood and Cell Technologies Company
Overseas, revenue was up 13.1% over the same period of the previous fiscal year as the business for blood
centers in Americas and Asia and others was strong. In Japan, revenue increased 7.3% year on year owing to theincrease in sales of automated blood component collection products. As a result, global revenue increased 12.7%
over the same period of the previous fiscal year to ¥127.8 billion.

－ 4 －Terumo Corporation (4543) Consolidated Financial Results for the Nine Months Ended December 31, 2023

(2) Overview of Consolidated Statement of Financial Position
Total assets stood at ¥1,691.7 billion, an increase of ¥89.4 billion. This was mainly owing to the impacts of
yen weakness in foreign exchange rates (hereinafter referred to as “FX impacts”) and increase in revenue,
which resulted in an increase in trade and other receivables of ¥27.5 billion, an increase in inventories of ¥22.9
billion due to FX impacts, as well as property, plant and equipment of ¥18.7 billion and goodwill andintangible assets of ¥20.6 billion due to FX impacts and investment in manufacturing facility and new IT
systems. This offset the decrease in cash and cash equivalents of ¥23.7 billion from acquisition of treasury
share.
Total liabilities came to ¥475.7 billion, a decrease of ¥15.5 billion. This was mainly due to an increase in othercurrent liabilities of ¥7.4 billion yen resulting from FX impacts, which was offset by a decrease in trade andother receivables of ¥10.4 billion yen owing to payments related to equipment, a decrease in bonds andborrowings of ¥5.7 billion due to the redemption of corporate bonds, and a decrease in current taxes liabilitiesof ¥3.6 billion from the payment of income tax.
Total equity was ¥1,216.0 billion, an increase of ¥104.9 billion. This mainly reflects an increase from posting
profit for the period of ¥79.9 billion, while the booking of other comprehensive income associated with FX
impacts resulted in a ¥64.8 billion increase, which offset the decrease of ¥32.0 billion from dividends fromretained earnings and a decrease of ¥7.9 billion from the acquisition of treasury shares.
(3) Guidance, including the Consolidated Financial Results for the Fiscal Year Ending March 31, 2024
We upwardly revised our full-year consolidated financial guidance for Revenue, Adjusted operating profit,
Operating profit and Profit for the year attributable to owners of the parent respectively. In addition to strong
earnings performance in each business segment, yen is depreciating in value in contrast with our foreignexchange rates at the start of the fiscal year. For details, please refer to the “Notice Concerning Revision of the
Full-Year Financial Guidance for Fiscal Year Ending March 31, 2024 (FY2023)” released on February 7,
2024.

－ 5 －

Terumo Corporation (4543) Consolidated Financial Results for the Nine Months Ended December 31, 2023

2. Condensed Quarterly Consolidated Financial Statements(1) Condensed Quarterly Consolidated Statement of Financial Position（Unit: Millions of yen）
As of
December 31, 2023

As ofMarch 31, 2023
AssetsCurrent assets
Cash and cash equivalents

187,322

163,633

Trade and other receivables

150,635

178,156

Other current financial assets

106

17,750249,618

272,500

Current tax assets

2,920

3,669

Other current assets

20,79333,301

Total current assets

611,396

669,012

Property, plant and equipment

370,869

389,536

Goodwill and intangible assets
Investments accounted for using
the equity method
Other non-current financial assets

538,210558,814

3,680

1,992

34,421

27,394

Deferred tax assets

20,45821,776

Other non-current assets

23,187

23,139Total non-current assets

990,829

1,022,655

1,602,225

1,691,667

Inventories

Non-current assets

Total assets－ 6 －Terumo Corporation (4543) Consolidated Financial Results for the Nine Months Ended December 31, 2023

（Unit: Millions of yen）
As of
December 31, 2023

As ofMarch 31, 2023
Liabilities and Equity
Liabilities
Current liabilities
Trade and other payables

97,73687,301

Bonds and borrowings

11,223

151,245

Other current financial liabilities

7,597

7,662

Current tax liabilities

23,563

19,916329

212

Other current liabilities

77,551

84,903

Total current liabilities

218,001

351,242

Bonds and borrowings
Other non-current financial
liabilities
Deferred tax liabilities

220,71474,976

29,63930,499

8,870

3,393

Retirement benefit liabilities

4,703

4,923

127

104

Other non-current liabilities

9,106

10,516

Total non-current liabilities

273,161

124,413491,162475,656

Share capital

38,716

38,716

Capital surplus

51,75951,690Treasury shares(11,539)(19,076)

Retained earnings

874,272

922,094

Other components of equity
Total equity attributable to owners of
the parent
Total equity

157,855

222,586

1,111,063

1,216,011

1,111,063

1,216,011

1,602,225

1,691,667

Provisions

Non-current liabilities

Provisions

Total liabilities
EquityTotal liabilities and equity－ 7 －Terumo Corporation (4543) Consolidated Financial Results for the Nine Months Ended December 31, 2023

(2) Condensed Quarterly Consolidated Statement of Profit or Loss and Condensed Quarterly Consolidated
Statement of Comprehensive Income(Condensed Quarterly Consolidated Statement of Profit or Loss)（Unit: Millions of yen）
For the nine months ended
For the nine months ended
December 31, 2022
December 31, 2023
Revenue
617,993682,951
Cost of sales
299,646
328,111Gross profit
318,347
354,840
Selling, general and administrative expenses
224,136
251,309
Other income
8,226
4,320
Other expenses
8,922
2,332
Operating profit
93,514
105,519
Finance income
1,915
2,487
Finance costs
3,466
2,288
Share of profit of investments accounted for
136
25
using the equity method
Profit before tax
92,100105,743
Income tax expenses
21,92025,846
Profit for the period
70,18079,897
Attributable to:
Owners of the parent
Total profit for the period

70,18070,18079,897
79,897

Earnings per share
Basic earnings per share (yen)Diluted earnings per share (yen)

93.25
93.21

107.33107.29－ 8 －Terumo Corporation (4543) Consolidated Financial Results for the Nine Months Ended December 31, 2023

(Condensed Quarterly Consolidated Statement of Comprehensive Income)

Profit for the period

For the nine months ended
December 31, 2022
70,180

Other comprehensive income
Items that will not be reclassified to profit orloss
Changes in financial assets measured at fairvalue through other comprehensive income
Remeasurements of defined benefit plans
Total items that will not be reclassified to
profit or loss
Items that are or may be reclassified
subsequently to profit or loss
Exchange differences on translation offoreign operations
Cash flow hedges
Cost of hedging
Total items that are or may be reclassified
subsequently to profit or loss
Total other comprehensive income
for the period
Total comprehensive income for the period（Unit: Millions of yen）
For the nine months ended
December 31, 2023
79,897

1,982

991

864

122

2,847

1,114

65,72363,932

734

30

(341)

(311)

66,11763,65068,96464,764

139,144

144,662

139,144

144,662

139,144

144,662

Attributable to:
Owners of the parent
Total comprehensive income for the period(Note) Items in the above statement are net of tax.

－ 9 －Terumo Corporation (4543) Consolidated Financial Results for the Nine Months Ended December 31, 2023

(3) Condensed Quarterly Consolidated Statement of Changes in Equity
For the nine months ended December 31, 2022
Equity attributable to owners of the parent
Other
Capital Treasury Retained
components
surplussharesearnings
of equity

Share
capitalBalance as of April 1, 2022

（Unit: Millions of yen）

Total

Total equity

38,71651,921(6,229)846,978

Profit for the period

-

-

-

70,180-70,18070,180

Other comprehensive income

-

-

-

-

68,964

68,964

68,964---70,18068,964

139,144

139,144

Acquisition of treasury shares

-

(56)

(50,002)-- (50,058)(50,058)

Disposal of treasury shares

-

17

87

-

Dividends
Transfer from othercomponents of equity toretained earnings
Share-based payments
Total transactions with owners of
the parent
Balance as of December 31, 2022 38,716--(27,924)

-

-

2,758

(2,758)

-

-

54

123

-

57

235

235

15

(49,791)(25,165)(2,805) (77,747)(77,747)

51,937(56,020)

891,992

147,085 1,073,711

1,073,711

Total comprehensive income

80,926 1,012,313(105)

For the nine months ended December 31, 2023

Balance as of April 1, 2023

00- (27,924)(27,924)（Unit: Millions of yen）

Equity attributable to owners of the parent
Other
Capital Treasury Retained
components
surplussharesearnings
of equity

Share
capital1,012,313

Total

Total equity

38,71651,759(11,539)874,272

Profit for the period

-

-

-

79,897-

79,897

79,897

Other comprehensive income

-

-

-

-

64,76464,76464,764---

79,89764,764

144,662

144,662

Acquisition of treasury shares-(5)(7,942)--(7,947)(7,947)

Disposal of treasury shares

-

(104)

185

-

(81)

0

0

Dividends
Transfer from retained
earnings to capital surplus
Transfer from othercomponents of equity toretained earnings
Share-based payments
Total transactions with owners of
the parent
Balance as of December 31, 2023 38,716--(32,020)- (32,020)(32,020)

72

-

(72)

-

-

-

-

-

17

(17)

-

-

(31)

220

-

64

254

254

(68)

(7,536)(32,075)(33) (39,714)(39,714)51,690(19,076)922,094

222,586 1,216,011

1,216,011

Total comprehensive income－ 10 －

157,855 1,111,063

1,111,063

Terumo Corporation (4543) Consolidated Financial Results for the Nine Months Ended December 31, 2023

(4) Notes Pertaining to Condensed Quarterly Consolidated Financial Statements(i) Going concern assumption
Not applicable(ii) Changes in accounting policy
The Group has adopted the standard and interpretation below from the first quarter of the fiscal year ending
March 31, 2024.
Standard/Interpretation
IAS 12

Income taxes

Outline of the new standards, interpretations and amendments
Clarification of the accounting for deferred tax on leases anddecommissioning obligations (Transactions for which companies
recognize both an asset and a liability)

There is no material effect of adopting these standards on the Group’s condensed quarterly consolidated
financial statements for the nine months ended December 31, 2023.
(iii) Segment information(1) General information on reportable segments
The reportable segments of the Group represent business units for which separate financial information isavailable, and are reviewed regularly at the Board of Directors meeting to make decisions about allocation ofmanagement resources and assess the performance of the business.
The Group applies an in-house company system classified by product groups. The headquarters of each inhouse company plan their own comprehensive domestic and international strategies and conduct their own
business activities.
The three segments are Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell
Technologies Company.

－ 11 －

Terumo Corporation (4543) Consolidated Financial Results for the Nine Months Ended December 31, 2023

(2) Reportable segment information
Revenue and operating results of the reporting segments of the Group are described below.
For the nine months ended December 31, 2022

Reportable Segments

Revenue
Revenue from sales
to externalcustomers
Segment profit(Adjusted
operatingprofit)(Adjustment item)
Amortization of
intangible assets
acquired throughbusiness
combinations
Non-recurring profit orloss(Note 2)(Unit: Millions of yen)Amountrecorded oncondensed
Adjustments
quarterly(Note 1)
consolidated
financialstatements

Cardiac and
VascularCompany

MedicalCare
SolutionsCompany

Blood and
Cell
Technologies
Company

358,907

145,511

113,388617,807186

617,993

83,59812,605

12,924

109,127479

109,607(6,770)-(7,633)(14,403)4(14,399)

Total(1,694)

Operating profit

93,514

Finance income

1,915

Finance costs
Share of profit/(loss) ofinvestment accounted
for using the equity
methodProfit before tax(3,466)
136
92,100(Note 1) Amounts in “Adjustments” are as follows:(1) ¥186 million adjustment to Revenue from sales to external customers is mainly proceeds fromoutward temporary staffing that is not attributable to reportable segments.
(2) ¥479 million adjustment to Segment profit consists of ¥(2,511) million for preparation expenses tocomply with Medical Device Regulation in EU and ¥(359) million for inventories.
(Note 2) ¥(1,694) million Non-recurring profit or loss mainly includes ¥(1,788) million for impairment lossof technologies, ¥(3,589) million for impairment loss of goodwill, ¥(1,564) million for businessreorganization expenses, ¥1,357 million for the change in fair value of contingent considerationand ¥3,891 million for gain on business transfer and other.

－ 12 －

Terumo Corporation (4543) Consolidated Financial Results for the Nine Months Ended December 31, 2023

For the nine months ended December 31, 2023

Reportable Segments

Revenue
Revenue from sales
to externalcustomers
Segment profit(Adjusted
operatingprofit)(Adjustment item)
Amortization of
intangible assets
acquired throughbusiness
combinations
Non-recurring profit orloss(Note 2)(Unit: Millions of yen)Amountrecorded oncondensed
Adjustments
quarterly(Note 1)
consolidated
financialstatements

Cardiac and
VascularCompany

MedicalCare
SolutionsCompany

Blood and
Cell
Technologies
Company

407,700

147,279

127,799

682,779172

682,951

91,992

15,993

13,869

121,855(2,121)

119,733(7,072)-(7,912)(14,984)306(14,677)

Total

463

Operating profit

105,519

Finance income

2,487

Finance costs
Share of profit/(loss) ofinvestment accounted
for using the equity
methodProfit before tax(2,288)
25
105,743(Note 1) Amounts in “Adjustments” are as follows:(1) ¥172 million adjustment to Revenue from sales to external customers is mainly proceeds fromoutward temporary staffing that is not attributable to reportable segments.
(2) ¥(2,121) million adjustment to Segment profit consists of ¥(1,945) million for preparation
expenses to comply with Medical Device Regulation in EU and ¥(881) million for inventories.
(Note 2) ¥463 million Non-recurring profit or loss mainly includes ¥1,335 million for gain on sale of sharesof subsidiaries and affiliate, which is related to the sale of shares of Olympus Terumo
Biomaterials Corporation and ¥(1,125) million for business reorganization expenses.

－ 13 －

Terumo Corporation (4543) Consolidated Financial Results for the Nine Months Ended December 31, 2023(iv) Impairment of non-financial assets
In the nine months ended December 31, 2023, ¥1,844 million for an impairment loss in property, plant andequipment in Blood and Cell Technologies Company was recorded due to the decision not to put certain
manufacturing facilities into operation.
The recoverable amount was measured based on the value in use, and the value was determined to be zero. The
impairment loss in property, plant and equipment is included in “Cost of sales” in the Condensed Quarterly
Consolidated Statement of Profit or Loss.
(v) Material subsequent events
Share split
The Company has resolved, at the meeting of the Board of Directors held on February 7, 2024, to conduct share
split and partial amendment to the Articles of Incorporation.
(1) Purpose of share split
The objective of the share split is to lower the investment price per trading unit to create a more investor-friendly
environment.
(2) Overview of share splita) Method of share split
Each share of the Company’s common stock owned by shareholders recorded in the closing register ofshareholders on the record date of March 31, 2024*1 will be split into two shares.
*1Since this day falls on a non-business day of the shareholder registry administrator, the actual record
date will be March 29, 2024.
b) Number of shares to be increased by share split
Total number of issued shares before the share split

747,682,540 shares*2

Number of shares to be increased by the share split

747,682,540 shares*2

Total number of issued shares after the share split

1,495,365,080 shares*2

Total number of shares authorized to be issued after
the share split

5,900,000,000 shares*2As of February 7, 2024. The Company is acquiring its own shares of up to 20 billion yen in value in aperiod from August 14, 2023 to March 8, 2024, and plans to cancel all of the acquired shares on March 19,2024. Due to a change in the total number of issued shares resulted from the cancellation of the acquired
shares, the total number of issued shares before the share split, the number of shares to be increased by theshare split and the total number of issued shares after the share split will be changed.
c) Timetable
Date of public notice of the record date

March 11, 2024

Record date

March 31, 2024

Effective date

April 1, 2024d) Others- The share split will not result in any change in the amount of the Company’s share capital.
- As the share split is scheduled to take effect on April 1, 2024, the year-end dividend for fiscal year ending
March 2024 with a record date of March 31, 2024 will be made based on the number of shares before theshare split.
(3) Partial amendment to the Articles of Incorporationa) Reason for the amendment
Due to the share split described above, the Company will amend the total number of shares authorized to－ 14 －

Terumo Corporation (4543) Consolidated Financial Results for the Nine Months Ended December 31, 2023

be issued described in Article 6 of its Articles of Incorporation with an effective date of April 1, 2024,
pursuant to Paragraph 2 of Article 184 of the Companies Act of Japan.
b) Detail of the amendment（Changed portions are underlined)
Current Articles of Incorporation(Total Number of Shares Authorized to be Issued)
Article 6.
The total number of shares authorized to be issued
by the Company shall be three billion thirty-eight
million (3,038,000,000).

Articles of Incorporation after amendment(Total Number of Shares Authorized to be Issued)
Article 6.
The total number of shares authorized to be issued
by the Company shall be five billion nine hundred
million (5,900,000,000).

c) Timetable
Date of resolution at the meeting of the Board of
Directors

February 7, 2024

Effective date

April 1, 2024

(4) Earnings per share
Assuming that the share split was carried out at the beginning of the previous fiscal year, earnings per share are as
follows:
For the nine months ended
December 31, 2022

For the nine months ended
December 31, 2023

Basic earnings per share (yen)

46.62

53.66

Diluted earnings per share (yen)

46.60

53.64

－ 15 －